Capmatinib (TABRECTA) approved by FDA in May 2020 for the treatment of non-small cell lung cancer. Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with antineoplastic activity. It selectively binds to c-Met,  inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. Capmatinib contains 2-fluoro-N-methylbenzamide moiety in its backbone.

We have made a set of in-stock Building Blocks, which contain such part – the perfect start for your research!